At the 2019 AAD meeting, 5-year follow-up data from the extension cohort of the phase 3 core trials ERASURE/FIXTURE was presented that showed that the IL-17A blocker secukinumab maintains long-term high levels of efficacy[1, 2].
Patients from the ERASURE/FIXTURE trials who gained a 75% response in the Psoriasis Area and Severity Index (PASI) were randomised in 2:1 ratio at week 52 to either the same dose of secukinumab (300 mg/150 mg, continuous-treatment) or placebo (treatment-withdrawal) every 4 weeks, until week 156 or relapse, defined as a >50% reduction in maximal PASI from core study baseline. Patients experiencing relapse with placebo received secukinumab. At week 156, all patients received open-label secukinumab treatment with those on 300 mg continuing 300 mg and those on 150 mg opting to receive 150 mg or 300 mg.
PASI responses were sustained with secukinumab until week 260 (PASI 75/90/100: 85.1%/67.2%/37.8%). “Over 60% of patients were clear or almost clear according to the global assessment of the investigators up to 5 years,” said Prof. Richard Langley (Dalhousie University, Canada) during the presentation. In patients treated with 300 mg secukinumab, the mean PASI score was 2.2 at week 260. In addition, secukinumab had a favourable safety profile with no increase in adverse events over time. Long-term treatment with secukinumab revealed no new safety signals. In addition, the treatment had a long-term favourable effect on quality of life.
keywords: secukinumab, psoriasis, interleukin, IL-17
- Langley RG, et al. N Engl J Med 2014;371:326-38.
- Langley RG. Abstract 10052, AAD Annual Meeting, 1-5 March 2019, Washington DC, USA.
The content and interpretation of these conference highlights are the views and comments of the speakers/authors.